Date: 01 Dec 2005
Prescription versus herbal medications for prostate cancer prevention: Why history cannot be allowed to repeat itself in your clinical practice
- Mark A. Moyad MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
It is obvious that herbal dietary supplements have enjoyed a great deal of popularity and sales throughout the past decade and, in the area of prostate cancer prevention, this is especially the case. However, the lack of currently available evidence to indicate their effectiveness truly is a potential problem. In addition, the quality control, safety, and regulatory issues abound. However, regardless of this, one only needs to point toward the history of specific supplements for the prevention and treatment of cancer throughout the past 30 years to realize that there indeed is reason for concern. Beta-carotene supplements, shark cartilage, PC-SPES, vitamin C, and zinc are just a few examples of why clinicians cannot let history repeat itself. In other words, until the results of large randomized trials are published, the best course of action may be promoting no action at all. Lifestyle changes, supplements, and prescription medications that promote overall heart health for patients who qualify seem to make the most sense at this time because even in the worst-case scenario, patients still benefit. Most of the herbal medications that seem promising (eg, flaxseed) have been studied mostly using the dietary, not the supplement form, and this has to be emphasized to patients. The herbal prostate health supplements such as saw palmetto, pygeum, stinging nettle, and others have no adequate clinical data to suggest any impact on cancer prevention. However, their use by individuals at screening sites increases the probability that history may unfortunately repeat itself.
References and Recommended Reading
Eisenberg DM, David RB, Ettner SL, et al.: Trends in alternative medicine use in the United States. JAMA 1998, 280:1569–1575.PubMed
Ciocon JO, Ciocon DG, Galindo DJ: Dietary supplements in primary care: botanicals can affect surgical outcomes and follow-up. Geriatrics 2004, 59:20–24.PubMed
Bluementhal M: Herb sales down in mainstream market, up in natural food stores. Herbal Gram 2002, 55:60.
Matthews MK Jr: Association of ginkgo biloba with intracerebral hemorrhage Neurology 1998, 50:1933–1934.PubMed
Turner RB, Bauer R, Woelkart K, et al.: An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl JMed 2005, 353:341–348. Most recent review of Echinacea angustifolia.
Mullins RJ: Echinacea-associated anaphylaxis. Med J Aust 1998, 168:170–171.PubMed
Boullata JI, Nace AM: Safety issues with herbal medicine. Pharmacotherapy 2000, 20:257–269.PubMed
Rose KD, Croissant PD, Parliament CF, Levin MB: Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990, 26:880–882.PubMed
Vuksan V, Sievenpiper JL, Koo VY, et al.: American ginseng (Panax quinquefolius L) reduces postpradial glycemia in nondiabetic subjects and subjects with type-2 diabetes mellitus. Arch Intern Med 2000, 160:1009–1013.PubMed
Kuo SC, Teng CM, Lee JC, et al.: Antiplatelet components in Panax ginseng. Planta Med 1990, 56:164–167.PubMed
NIH State-of-the-Science Panel: National Institutes of Health State-of-the-Science Conference Statement: management of menopause-related symptoms. Ann Intern Med 2005, 142:1003–1013. Offers best discussion of menopause-related symptoms.
North American Menopause Society: Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004, 11:11–33.
Bent S, Kane CJ, Shinohara K, et al.: A randomized, controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia [Abstract #1637]. J Urol 2005, 173(suppl):443.
Ernst E: Second thoughts about safety of St. John’s wort. Lancet 1999, 354:2014–2016.PubMed
Garges HP, Varia I, Doraiswamy PM: Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998,280:1566–1567.PubMed
Terris MK, Issa MM, Tacker RJ: Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001, 57:26–29.PubMed
Jatoi A, Ellison N, Burch PA, et al.: A phase-II trial of green tea in the treatment of patients with androgen-independent metastatic prostate carcinoma. Cancer 2003, 97:1442–1446.PubMed
Tsubono Y, Nishino Y, Komatsu S, et al.: Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001, 344:632–636.PubMed
Steinmetz KA, Potter JD: Vegetables, fruit, and cancer: I. Epidemiology. Cancer Causes Control 1991, 2:325–357.PubMed
Steinmetz KA, Potter JD: Vegetables, fruit, and cancer: II. Mechanisms. Cancer Causes Control 1991, 2:427–442.PubMed
Peto R, Doll R, Buckley JD, Sporn MB: Can dietary beta-carotene materially reduce human cancer rates? Nature 1981, 290:201–208.PubMed
World Cancer Research Fund: Food, Nutrition, and the Prevention of ancer: A Global Perspective. Washington D.C.: American Institute for Cancer Research; 1997:136–142.
Schottenfield D, Fraumeni JF Jr: Cancer Epidemiology and Prevention, edn 2. New York: Oxford University Press; 1996.
Lippman SM, Meyskens FL Jr: Vitamin A derivatives in the prevention and treatment of human cancer. J Am Coll Nutr 1988, 7:269–284.PubMed
Bendich A: Carotenoids and the immune response. J Nutr 1988, 119:112–115.
Sun Y: Free radicals, antioxidant enzymes, and carcinogenesis. Free Radie Biol Med 1990, 8:583–599.
Bryla P, Weyand EH: Role of activated oxygen species in benzo[a]pyrene: DNA adduet formation in vitro. Free Radie Biol Med 1991, 11:17–24.
Salgo MG, Cueto R, Winston GW, Pryor WA: Beta-carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA. Free Radie Biol Med 1999, 26:162–173.
van Poppel G: Carotenoids and cancer: an update with emphasis on human intervention studies. EurJ Can 1993, 29A:1335–1344.
Gann PH, Ma J, Giovannucci E, et al.: Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999, 59:1225–1230.PubMed
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl JMed 1994, 330:1029–1035.
Heinonen OP, Albanes D, Virtamo J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440–446.PubMed
Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150–1155.PubMed
Omenn GS, Goodman GE, Thornquist MD, et al.: Risk factors for lung cancer and for intervention effects in CARET: the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996, 88:1550–1559.PubMed
Palozza P, Caviello G, Bartoli GM: Pro-oxidant activity of beta-carotene under 100% oxygen pressure in rat liver microsomes. Free Radic Biol Med 1995, 19:887–892.PubMed
Burton GW, Ingold KU: Beta-carotene: an unusual type of lipid antioxidant. Science 1984, 224:569–573.PubMed
Terao Y, Yamauchi R, Murakami H, Matsushita S: Inhibitory effects of tocopherols and beta-carotene on singlet oxygen-initiated photooxidation of methyl linoleate and soybean oil. J Food Present 1980, 4:79–93.
Wang XD, Liu C, Bronson RT, et al.: Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke J Natl Cancer Inst 1999, 91:60–66.PubMed
DiPaola RS, Zhang H, Lambert GH, et al.: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998, 339:785–791.PubMed
Moyad MA, Pienta KJ, Montie JE: Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology 1999, 54:319–323.PubMed
Pfeifer BL, Pirani JF, Hamann SR, Klippel KF: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000, 85:481–485.PubMed
de la Taille A, Buttyan R, Hayek O, et al.: Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000, 164:1229–1234.
Porterfield H: UsToo PC-SPES surveys: review of studies and update of previous survey results. Mol Urol 2000, 4:289–291.PubMed
Small EJ, Frohlich MW, Bok R, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000, 18:3595–3603.PubMed
Oh WK, George DJ, Hackmann K, et al.: Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57:122–126.PubMed
Guns ES, Goldenberg SL, Brown PN: Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 2002, 9:1684–1688.PubMed
Sovak M, Seligson AL, Konas M, et al.: Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002, 94:1275–1281.PubMed
Fleshner N, Harvey M, Adomat H, et al.: Evidence for contamination of herbal erectile dysfunction products with phospho-diesterase type-5 inhibitors. J Urol 2005, 174:636–641.PubMed
Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I): extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 1990, 51:181–186.PubMed
Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer] Clin 1999, 49:362–375.
Moyad MA: The ABCs of Nutrition and Supplements for Prostate Cancer. Chelsea, MI: Sleeping Bear Press; 2000. Very concise review of the use of supplements for the treatment of prostate cancer.
Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998, 16:3649–3655.PubMed
Ashar B, Vargo E: Shark cartilage-induced hepatitis. Ann Intern Med 1996, 125:780–781.PubMed
Gonzalez JA, Kernen KM, Peters KM, et al: The oral administration of powdered shark cartilage for the treatment of advanced prostate cancer. Abstract presented at the Michigan Urologie Annual Meeting; 1996.
Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998, 2:146–152.PubMed
Berndt SI, Carter HB, Landis PL, et al.: Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 2005, 21:686–690.PubMed
Cameron E, Campbell A: The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974, 9:285–315.PubMed
Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976, 73:3685–3689.PubMed
Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: re-evaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978,75:4538–4542.PubMed
Creagan ET, Moertel CG, O’Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Eng J Med 1979, 301:687–690.
Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized, double-blind comparison. N Eng J Med 1985, 312:137–141.
Pauling L: Vitamin C therapy of advanced cancer. N Engl J Med 1980, 302:694–695.PubMed
Podmore I, Griffiths HR, Herbert KE, et al.: Vitamin C exhibits pro-oxidant properties. Nature 1998, 392:559.PubMed
Agus DB, Vera JC, Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999, 59:4555–4558.PubMed
Levine ML, Corry-Cantilena C, Wang Y, et al.: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996, 93:3704–3709.PubMed
Blanchard J, Tozer TN, Rowland M: Pharmacokinetic perspectives on mega doses of ascorbic acid. Am J Clin Nutr 1997, 66:1165–1171.PubMed
Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS: Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomized trial. Lancet 1999, 354:2025–2028.PubMed
Jacques PF, Taylor A, Hankinson SE, et al.: Long-term vitamin C supplement use and prevalence of early age-related lens opacities. Am J Clin Nutr 1997, 66:911–916.PubMed
Nyyssonen K, Parviainen MT, Salonen R, et al.: Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997, 314:634–638.PubMed
Briefel RR, Bialostosky K, Kennedy-Stephenson J, et al.: Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988–1994. J Nutr 2000, 130(suppl):1367S-1373S.PubMed
Food and Nutrition Board, National Academy of Sciences: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Co per, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington D.C.:National Academy Press; 2001.
Leitzmann MF, Stampfer MJ, Wu K, et al.: Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2002, 95:1004–1007. Discusses, in detail, the role zinc plays in prostate cancer.
Ishii K, Usui S, Sugimura Y, et al.: Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull 2001, 24:226–230.PubMed
Ishii K, Usui S, Sugimura Y, et al.: Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001, 92:49–64.PubMed
Feng P, Liang JY, Li TL, et al.: Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol 2000, 4:31–36.PubMed
Feng P, Liang JY, Li TL, et al.: Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999, 40:200–207.PubMed
Iguchi K, Hamatake M, Ishida R, et al.: Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur J Biochem 1998, 253:766–770.PubMed
Zaichick V, Sviridova TV, Zaichick SV: Zinc in the human prostate gland: normal, hyperplasic, and cancerous. Int Urol Nephrol 1997, 29:565–574.PubMed
Nemoto K, Kondo Y, Himeno S, et al.: Modulation of telomerase activity by zinc in human prostatic and renal cancer cells. Biochem Pharmacol 2000, 59:401–405.PubMed
Sommerfeld HJ, Meeker AK, Piatyszek MA, et al.: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996, 56:218–222.PubMed
Boissier S, Ferreras M, Peyruchaud O, et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60:2949–2954.PubMed
Holmes MD, Pollak MN, Willett WC, Hankinson SE: Dietary correlates of plasma insulin-like growth factor-1 and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002, 11:852–861.PubMed
Prasad AS, Mantzoros CS, Beck FW, et al.: Zinc status and serum testosterone levels of healthy adults. Nutrition 1996, 12:344–348.PubMed
Lagiou P, Wuu J, Trichopoulou A, et al.: Diet and benign prostatic hyperplasia: a study in Greece. Urology 1999, 54:284–290.PubMed
Dunzendorfer U, Drahovsky D: C-peptide, testosterone, estrogen, cortisol, and zinc in patients with benign prostatic hyperplasia of the prostate Urol Int 1980, 35:369–374.PubMed
Feustel A, Wenrich R: Zinc and cadmium in cell fractions of prostatic cancer tissues of different histological grading in comparison to BPH and normal prostate. Urol Res 1984, 12:147–150.PubMed
Brys M, Nawrocka AD, Miekos E, et al.: Zinc and cadmium analysis in human prostate neoplasms. Biol Trace Elem Res 1997, 59:145–152.PubMed
Leake A, Chrisholm GD, Busuttil A, et al.: Subcellular distribution of zinc in the benign and malignant human prostate: evidence for a direct zinc androgen interaction. Acta Endocrinol (Copenh) 1984, 105:281–288.
Leake A, Chrisholm GD, Habib FK: The effect of zinc on the 5 alpha-reduction of testosterone by the hyperplastic human prostate gland. J Steroid Biochem 1984, 20:651–655.PubMed
Sazawai S, Black RE, Bhan MK, et al.: Efficacy of zinc supplementation in reducing the incidence and prevalence of acute diarrhea: a community-based, double-blind, controlled trial. Am] Clin Nutr 1997, 66:413–418.
Prasad AS, Fitzgerald JT, Bao B, et al.: Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate: a randomized, double-blind, placebo-controlled trial. Ann Int Med 2000, 133:245–252.PubMed
Macknin ML, Piedmonte M, Calendine C, et al.: Zinc gluconate lozenges for treating the common cold in children: a randomized, controlled trial. JAMA 1998, 279:1962–1967.PubMed
Irving JA, Mattman A, Lockitch G, et al.: Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. Can Med Assoc J 2003, 169:129–131.
Chandra RK: Excessive intake of zinc impairs immune responses. JAMA 1984, 252:1443–1446.PubMed
Samman S, Roberts DC: The effect of zinc supplements on lipoproteins and copper status. Atherosclerosis 1988, 70:247–252.PubMed
Schrauzer GN, White DA, Schneider CJ: Inhibition of the genesis of spontaneous mammary tumors in C3H mice: effects of selenium and of selenium-antagonistic elements and their possible role in human breast cancer. Bioinorg Chem 1976, 6:265–270.PubMed
Wiygul JB, Evans BR, Peterson BL, et al.: Supplement use among men with prostate cancer. Urology 2005, 66:161–166.PubMed
Neuhouser ML, Kristal AR, Patterson RE, et al.: Dietary supplement use in the prostate cancer prevention trial: implications for prevention trials. Nutr Cancer 2001, 39:12–18.PubMed
Weinrich SP, Hudson J, Moyad MA, Weinrich MC: Intake of selected nutritional supplements by African-American men. Urology 2004, 64:1094–1097.PubMed
Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMed
Gomella LG: Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005, 15:29–32.PubMed
Moyad MA: Lifestyle changes to prevent BPH: heart healthy = prostate healthy. Urol Nurs 2003, 23:439–441.PubMed
Moyad MA, Carroll PR: Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am 2004, 31:289–300.PubMed
Moyad MA, Carroll PR: Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin North Am 2004, 31:301–311.PubMed
Demark-Wahnefried W, Robertson CN, Walther PJ, et al.: Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004, 63:900–904.PubMed
Moyad MA: Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemo-prevention trial: part I. Urol Oncol 2004, 22:466–471.PubMed
Basier J, Piazza GA: Nonsteroidal anti-inflammatory drugs and cydooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004, 171:S59-S63.
Fagelman E, Lowe FC: Herbal medicines in the treatment of benign prostatic hyperplasia. Urol Clin North Am 2002, 29:23–29.PubMed
Lips P: Hypervitaminosis A and fractures. N Engl J Med 2003, 348:347–349.PubMed
Eyre H, Kahn R, Robertson RM, et al.: Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004, 109:3244–3255.PubMed
- Prescription versus herbal medications for prostate cancer prevention: Why history cannot be allowed to repeat itself in your clinical practice
Current Prostate Reports
Volume 3, Issue 4 , pp 160-168
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Mark A. Moyad MD (1)
- Author Affiliations
- 1. Department of Urology, University of Michigan Medical Center, 1500 East Medical Center Drive, 48109-0330, Ann Arbor, Ml, USA